All In Biotech

Drug Trial Radar · NCT02876328

Partnership for Research on Ebola VACcinations

Partnership for Research on Ebola VACcinations (PREVAC)

Last checked: Nov 19, 2026Latest source record: Jun 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 4,789 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,789

Actual

Start

Mar 27, 2017

Primary completion

Dec 24, 2019

Study completion Dec 20, 2023

Sponsor

Sponsor type
NIH
Collaborators
Partnership for Research on Ebola Virus in Liberia (PREVAIL); Institut National de la Santé Et de la Recherche Médicale, France; London School of Hygiene and Tropical Medicine; European and Developing Countries Clinical Trials Partnership (EDCTP)
First posted
Aug 23, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults. Participants will receive either the Ad26.ZEBOV (rHAd26) vaccine with a MVA-BN-Filo (MVA) boost, or the rVSVΔG-ZEBOV-GP (rVSV) vaccine with or without boosting, or placebo.

Conditions

  • Ebola Virus Disease

Interventions

  • Ad26.ZEBOVBiological

    0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children

  • MVA-BN-FiloBiological

    0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children

  • rVSVΔG-ZEBOV-GPBiological

    1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children

  • PlaceboBiological

    0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children

  • rVSV boostBiological

    1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Ebola Virus Glycoprotein (GP-EBOV) Antibody ResponseTime frame: Measured through Month 12

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • Centre national de formation et de recherche en santé rurale (Maferyniah)

    Conakry, Guinea

  • Landreah

    Conakry, Guinea

  • The Redemption Hospital

    Monrovia, Liberia

  • Centre pour le Développement des Vaccins (CVD)

    Bamako, Mali

  • University Clinical Research Center (UCRC)

    Bamako, Mali

  • Mambolo Clinic

    Kapesseh, Sierra Leone

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.